Cyclarity Launches Human Trial for Atherosclerosis

Cyclarity Therapeutics, a biotechnology company based at the Buck Institute in California, has launched its first human clinical trial. Its primary candidate cyclodextrin drug, UDP-003, focuses on addressing atherosclerosis, a condition characterized by the buildup of fats, cholesterol, and other substances in and on the artery walls. This trial represents a pivotal moment in the field of rejuvenation biotechnology and life extension technologies, as it aims to directly combat one of the leading causes of heart disease and stroke, which are significant contributors to mortality worldwide. The initiation of this human trial underscores the potential of targeted therapies in extending human healthspan and lifespan, offering hope for more effective treatments against age-related diseases.